Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
Open Access
- 13 January 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 117 (2), 542-552
- https://doi.org/10.1182/blood-2010-02-269514
Abstract
Bortezomib induces remissions in 30%-50% of patients with relapsed mantle cell lymphoma (MCL). Conversely, more than half of patients' tumors are intrinsically resistant to bortezomib. The molecular mechanism of resistance has not been defined. We generated a model of bortezomib-adapted subclones of the MCL cell lines JEKO and HBL2 that were 40- to 80-fold less sensitive to bortezomib than the parental cells. Acquisition of bortezomib resistance was gradual and reversible. Bortezomib-adapted subclones showed increased proteasome activity and tolerated lower proteasome capacity than the parental lines. Using gene expression profiling, we discovered that bortezomib resistance was associated with plasmacytic differentiation, including up-regulation of IRF4 and CD38 and expression of CD138. In contrast to plasma cells, plasmacytic MCL cells did not increase immunoglobulin secretion. Intrinsically bortezomib-resistant MCL cell lines and primary tumor cells from MCL patients with inferior clinical response to bortezomib also expressed plasmacytic features. Knockdown of IRF4 was toxic for the subset of MCL cells with plasmacytic differentiation, but only slightly sensitized cells to bortezomib. We conclude that plasmacytic differentiation in the absence of an increased secretory load can enable cells to withstand the stress of proteasome inhibition. Expression of CD38 and IRF4 could serve as markers of bortezomib resistance in MCL. This study has been registered at http://clinicaltrials.gov as NCT00131976.Keywords
This publication has 57 references indexed in Scilit:
- BCL6, MUM1, and CD10 Expression in Mantle Cell LymphomaApplied Immunohistochemistry & Molecular Morphology, 2010
- XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell developmentThe Journal of Experimental Medicine, 2009
- ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- One step at a time: endoplasmic reticulum-associated degradationNature Reviews Molecular Cell Biology, 2008
- Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma CellsMolecular Cancer Research, 2008
- IRF4 addiction in multiple myelomaNature, 2008
- Signal integration in the endoplasmic reticulum unfolded protein responseNature Reviews Molecular Cell Biology, 2007
- Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cellsBlood, 2006
- A loss-of-function RNA interference screen for molecular targets in cancerNature, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005